Stryker Corporation
SYK
$319.87
-3.42%
Stryker Corporation is a leading medical technology company that designs, manufactures, and markets a broad portfolio of medical equipment, instruments, consumable supplies, and implantable devices, primarily serving the orthopedic and surgical markets. As one of the three largest competitors in reconstructive orthopedic implants and the leader in operating room equipment, Stryker holds a dominant competitive position in the medical devices industry. The current investor narrative centers on Stryker's ability to sustain growth through strategic acquisitions, such as the recent Amplitude Vascular Systems deal, while navigating margin pressures and a challenging macroeconomic environment that has weighed on the stock's performance.…
SYK
Stryker Corporation
$319.87
Related headlines
SYK 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Stryker Corporation's 12-month outlook, with a consensus price target around $386.52 and implied upside of +20.8% versus the current price.
Average Target
$386.52
0 analysts
Implied Upside
+20.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$315 - $465
Analyst target range
Stryker is covered by 25 analysts, with a consensus recommendation of 'Buy' and a mean recommendation score of 1.63 (where 1 is Strong Buy and 5 is Sell). The average price target is $386.52, implying approximately 22.1% upside from the current price of $316.44. The distribution leans bullish, with no sell ratings in the recent institutional ratings data, which includes upgrades from BMO Capital and reaffirmations from Evercore ISI and Leerink Partners. The target range spans from a low of $315.00 to a high of $465.00, indicating a wide dispersion of views. The high target of $465 assumes successful execution of growth strategies and margin expansion, while the low target of $315 suggests risks from competitive pressures or macroeconomic headwinds. The recent upgrade activity and positive sentiment support a constructive outlook, but the wide spread highlights uncertainty around the pace of recovery.
Bulls vs Bears: SYK Investment Factors
Stryker presents a mixed picture: its dominant market position, strong free cash flow, and healthy balance sheet support a bullish long-term thesis, while decelerating revenue growth, margin compression, and a premium trailing valuation raise concerns. The bull case is anchored by a 22% upside to the average analyst target and a forward P/E that appears reasonable if earnings rebound. However, the bear case highlights the risk of continued underperformance if growth fails to reaccelerate or margins remain under pressure. The single most important tension is whether Stryker can return to double-digit revenue growth and expand operating margins, which would justify its premium valuation; failure to do so could lead to further multiple compression. Currently, the evidence slightly favors the bull case given the strong analyst consensus and discounted forward valuation, but the stock's recent price action warrants caution.
Bullish
- 22% Upside to Analyst Target: The average analyst price target of $386.52 implies a 22.1% upside from the current price of $316.44, supported by a consensus Buy rating (mean 1.63 on a 1-5 scale). This reflects broad institutional confidence in Stryker's growth trajectory.
- Dominant Market Position in Orthopedics: Stryker is one of the top three players in reconstructive orthopedic implants and the leader in operating room equipment, with a diversified portfolio spanning MedSurg ($3.2B) and Orthopaedics ($2.8B) segments. This competitive moat supports stable revenue generation.
- Strong Free Cash Flow Generation: Trailing twelve-month free cash flow stands at $4.571 billion, providing ample capacity for strategic acquisitions (e.g., Amplitude Vascular Systems) and shareholder returns. The dividend yield of 0.96% and payout ratio of 39.6% indicate sustainable capital allocation.
- Healthy Balance Sheet with Low Leverage: Debt-to-equity ratio of 0.73 and current ratio of 1.89 indicate solid liquidity and manageable debt levels. This financial flexibility allows Stryker to invest in R&D ($413M in Q1 2026) and pursue M&A without straining its balance sheet.
Bearish
- Decelerating Revenue Growth: Q1 2026 revenue grew only 2.63% YoY to $6.02B, a sharp deceleration from Q4 2025's 11.4% growth. This slowdown suggests normalization after a post-pandemic surge and may signal maturing core markets.
- Trailing P/E Premium to Industry: The trailing P/E of 41.4x trades at a 66% premium to the medical devices industry average of ~25x. While the forward P/E of 18.9x appears more reasonable, it relies on significant earnings growth that may not materialize if margins remain compressed.
- Operating Margin Compression: Operating margin fell to 15.55% in Q1 2026 from 27.35% in Q4 2025, driven by higher SG&A ($2.28B) and R&D expenses. Sustained margin pressure could erode profitability and weigh on valuation multiples.
- Significant Underperformance vs. Market: Stryker's 1-year price change of -18.98% dramatically underperforms the S&P 500's +20.92% gain. The stock is trading near the low end of its 52-week range (78.1% of range), indicating persistent negative momentum and potential for further downside.
SYK Technical Analysis
Stryker's stock is in a sustained downtrend over the past year, with a 1-year price change of -18.98%, significantly underperforming the S&P 500's +20.92% gain. The current price of $316.44 sits at 78.1% of its 52-week range (low $281.00, high $404.87), indicating it is closer to the low end of the range. This positioning suggests the stock is in a bearish phase, potentially offering a value opportunity if fundamentals support a recovery, but also carrying the risk of further downside if negative momentum persists. The stock's beta of 0.778 implies it is less volatile than the market, which may provide some cushion during broad selloffs but also limits upside participation in rallies.
Beta
0.78
0.78x market volatility
Max Drawdown
-30.0%
Largest decline past year
52-Week Range
$281-$405
Price range past year
Annual Return
-17.8%
Cumulative gain past year
| Period | SYK Return | S&P 500 |
|---|---|---|
| 1m | +6.2% | +0.3% |
| 3m | -6.8% | +4.7% |
| 6m | -12.1% | +7.5% |
| 1y | -17.8% | +18.4% |
| ytd | -8.1% | +9.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
SYK Fundamental Analysis
Stryker's revenue trajectory shows moderate growth, with Q1 2026 revenue of $6.02 billion representing a 2.63% year-over-year increase, decelerating from the 7.2% growth seen in Q4 2025. The MedSurg segment contributed $3.207 billion and Orthopaedics $2.813 billion, with both segments showing steady demand. However, the deceleration in growth rate from prior quarters (Q4 2025: $7.171B, +11.4% YoY) suggests a normalization after a strong post-pandemic recovery, which may temper near-term growth expectations. The company remains profitable, with Q1 2026 net income of $745 million and a gross margin of 63.29%, which is stable but slightly compressed from 65.22% in Q4 2025. Operating margin declined to 15.55% from 27.35% in Q4 2025, partly due to higher SG&A and R&D expenses, though the net margin of 12.38% remains healthy. Stryker maintains a solid balance sheet with a debt-to-equity ratio of 0.73 and a current ratio of 1.89, indicating adequate liquidity. Free cash flow for the trailing twelve months was $4.571 billion, providing ample capacity for acquisitions and shareholder returns, though Q1 2026 free cash flow of $415 million was lower than prior quarters due to working capital changes.
Quarterly Revenue
$6.0B
2026-03
Revenue YoY Growth
+2.6%
YoY Comparison
Gross Margin
63.3%
Latest Quarter
Free Cash Flow
$4.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is SYK Overvalued?
Given Stryker's positive net income, the trailing P/E ratio of 41.40x is the primary valuation metric. The forward P/E of 18.93x implies a significant earnings growth expectation, as the market anticipates a sharp rebound in profitability. Compared to the medical devices industry average P/E of approximately 25x, Stryker's trailing multiple trades at a 66% premium, reflecting its market leadership and growth prospects. However, the forward P/E suggests a discount to the industry, indicating that the market expects earnings to catch up. Historically, Stryker's trailing P/E has ranged from 24x to 77x over the past five years, and the current 41.4x is near the middle of that range, suggesting it is not excessively overvalued relative to its own history. The P/S ratio of 5.35x is also above the industry average of 3.5x, but this premium is justified by Stryker's superior margins and market position.
PE
41.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 38x~46x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
23.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Stryker's trailing P/E of 41.4x is significantly above the industry average of 25x, implying high growth expectations that may not be met if revenue deceleration persists. The operating margin dropped to 15.55% in Q1 2026 from 27.35% in Q4 2025, driven by rising SG&A and R&D costs, which could compress earnings if not reversed. While free cash flow is strong at $4.57B TTM, the Q1 2026 free cash flow of $415M was notably lower than prior quarters due to working capital changes, signaling potential cash flow volatility. The debt-to-equity ratio of 0.73 is manageable, but any acquisition-related debt increase could strain the balance sheet.
Market & Competitive Risks: Stryker's stock has a beta of 0.778, indicating lower volatility than the market, but its 1-year relative strength of -39.9% versus the S&P 500 highlights severe underperformance. The medical devices sector faces pricing pressure from hospital consolidation and regulatory scrutiny, which could compress margins further. Competitive threats from peers like Boston Scientific and Johnson & Johnson in orthopedics and surgical equipment could erode market share. The recent acquisition of Amplitude Vascular Systems adds growth optionality but also integration risk.
Worst-Case Scenario: If Stryker fails to reignite revenue growth (e.g., below 2% YoY) and margins continue to compress, the stock could fall to its 52-week low of $281.00, representing a -11.2% decline from the current price of $316.44. In a severe downturn, the stock could approach the analyst low target of $315.00, which is essentially at current levels, but a broader market correction could push it to the 52-week low or below. Historical max drawdown of -29.97% suggests a potential decline to ~$221.50, though this is an extreme scenario. Realistically, an investor could lose approximately 11% to the 52-week low, or more if fundamentals deteriorate sharply.